Research Sample bioBank
Can’t find what you’re looking for? Contact us.
Or, need help ordering? 805.528.4341
Get Weekly Research Sample Updates in your Inbox:
Hepatitis B (HBV) Clinical Research Samples
Discovery Life Sciences provides the highest quality Hepatitis B (HBV) Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank.
- All Hepatitis B (HBV) Sample Orders are Packaged for Delivery within 24 Hours.
- All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
- Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
- Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations.
Advanced Data View:
Showing 133 of 133 total samples
Buy | Product ID | Sample | Origin | Matrix | Vial (ml) | Quantity | Price | Age | Gender | Ethnicity | Storage Temp | Sample Date | Test 1 | Test Data 1 | Sample Detail 1 | Test 2 | Test Data 2 | Sample Detail 2 | Test 3 | Test Data 3 | Sample Detail 3 | Product Details | Price | Buy | Additional Information 1 | Additional Data 1 | Additional Information 2 | Additional Data 2 | Additional Detail 2 | Additional Information 3 | Additional Data 3 | Additional Detail 3 | Additional Information 4 | Additional Data 4 | Additional Information 5 | Additional Data 5 | Additional Detail 5 | Additional Information 6 | Additional Data 6 | Additional Detail 6 | Additional Information 7 | Additional Data 7 | Additional Detail 7 | ICD10 codes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DLS12-0410 | Hepatitis B (HBV) | Italy | Plasma | 1.00 | 5.00 | $85.00 | 73 Y | M | White | <-70°C | 11-Sep-12 | Abbott Realtime PCR | 21,196 IU/mL | Siemens TruGene HCV | 1b | $85.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Dental Care | Symptoms | Fatigue | Additional Testing | ALT: 46; AST: 33; ALP: 44; LDH: 237; Bilirubin: 1.24; Serum Creatinine: 0.85 mg/dL; Chronic Hepatitis | Hepatitis Serology Result | anti-HCV+; anti-HBe+; HBeAg- (Abbott) | ||||||||||||||||
| DLS13-05043 | Hepatitis B (HBV) | Vietnam | Plasma | 1.00 | 3.00 | $85.00 | 24 Y | M | Asian | < -70C | 06-Jun-13 | Roche cobas | 71,800 IU/mL (HCV RNA); 195,000 (HBV RNA) | Real-Time PCR | 1 | $85.00 | 3-series HepB Vaccine | Partial | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice; Itching | Additional Testing | ALT: 178; AST: 138; Bilirubin: 57.9 umol/L; Serum Creatinine: 69 umol/L; Hepatitis C & B | Hepatitis Serology Result | HBsAg+; Anti HCV+ (ECLIA Cobas 6000) | Co-Infections | HBV+ | ||||||||||||||
| DLS13-11753 | Hepatitis B (HBV) | Germany | Serum | 1.00 | 2.00 | $55.00 | 30 Y | F | U/A | < -70C | 01-Apr-14 | Gene S Sequencing In-house Assay | 45 IU/mL | HBV PCR | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue | Hepatitis Serology Result | HBsAg+ (CMIA) | |||||||||||||||||||
| DLS13-11831 | Hepatitis B (HBV) | Italy | Plasma | 1.00 | 1.00 | $85.00 | 58 Y | M | White | < -70C | 27-Nov-13 | Roche cobas | 8,820 IU/mL (HBV); 207,000 IU/mL (HCV) | PCR Sequencing; Siemens TruGene HCV | D (HBV); 1b (HCV) | $85.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Sexual transmission | Symptoms | Fatigue | Additional Testing | ALT: 81; AST: 37; LDH: 383; Bilirubin: 0.6; Serum Creatinine: 0.7 mg/dL; Grade 1 Stage 2; Chronic Active Hepatitis due to HBV & HCV | Hepatitis Serology Result | HBsAg+; HDV Ab-; HBsAb-; HCV Ab+ (CMIA) | ||||||||||||||||
| DLS14-06862 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 2.00 | $55.00 | 43 Y | F | Asian | < -70C | 18-Jun-14 | Aptima HBV Quant Assay | 176,599 IU/mL | 21-Jun-16 | Real-Time PCR | C | Aptima HBV Quant Assay | 5.25 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Decreased appetite; Abdominal pain; Jaundice | Additional Testing | ALT: 48; AST: 27; Bilirubin: 19.2 umol/L; Serum Creatinine: 0.6 mg/dL | Hepatitis Serology Result | N/A | ||||||||||||
| DLS14-06868 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 1.00 | $55.00 | 49 Y | M | Asian | < -70C | 10-Jul-14 | Aptima HBV Quant Assay | 1,542 IU/mL | 21-Jun-16 | Real-Time PCR | C | Aptima HBV Quant Assay | 3019 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Decreased appetite; Fatigue; Jaundice | Additional Testing | ALT: 225; AST: 889; ALP: 188; Serum Creatinine: 0.7 mg/dL; Bilirubin: 108 umol/L | Hepatitis Serology Result | N/A | ||||||||||||
| DLS14-06871 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 3.00 | $55.00 | 59 Y | M | Asian | < -70C | 24-Jun-14 | Aptima HBV Quant Assay | 4,885 IU/mL | 21-Jun-16 | Real-Time PCR | C | Aptima HBV Quant Assay | 3.69 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Decreased appetite; Fatigue; Jaundice; Sleep disturbances | Additional Testing | ALT: 1263; AST: 1810; ALP: 185; Bilirubin: 365.8 umol/L; Serum Creatinine: 0.75 mg/dL | Hepatitis Serology Result | HBsAg+ (Elisa) | Aptima HBV Quant Assay | Positive | 13-Mar-2018 | |||||||||
| DLS14-06903 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 8.00 | $55.00 | 54 Y | M | Asian | < -70C | 18-Jun-14 | Aptima HBV Quant Assay | 11,900 IU/mL | 21-Jun-16 | Real-Time PCR | C | Aptima HBV Quant Assay | 4.08 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Decreased appetite; Abdominal pain; Jaundice; Itching; Sleep disturbances | Additional Testing | ALT: 1766; AST: 1659; Bilirubin: 176 umol/L; Serum Creatinine: 0.8 mg/dL | Hepatitis Serology Result | N/A | ||||||||||||
| DLS14-06931 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 3.00 | $55.00 | 20 Y | M | Asian | < -70C | 12-Jun-14 | Aptima HBV Quant Assay | 1,078 IU/mL | 21-Jun-16 | Real-Time PCR | C | Aptima HBV Quant Assay | 3.03 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Decreased appetite; Fatigue; Abdominal pain; Jaundice; Itching | Additional Testing | ALT: 267; AST: 237; Bilirubin: 199 umol/L; Serum Creatinine: 1.0 mg/dL | Hepatitis Serology Result | N/A | ||||||||||||
| DLS14-06938 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 7.00 | $55.00 | 43 Y | M | Asian | < -70C | 12-Jun-14 | Aptima HBV Quant Assay | 6,670 IU/mL | 21-Jun-16 | Real-Time PCR | C | Aptima HBV Quant Assay | 3.82 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Decreased appetite; Fatigue; Sleep disturbances | Additional Testing | ALT: 227; AST: 367; Bilirubin: 21.8 umol/L; Serum Creatinine: 0.8 mg/dL | Hepatitis Serology Result | N/A | ||||||||||||
| DLS14-06941 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 2.00 | $55.00 | 46 Y | F | Asian | < -70C | 13-Jun-14 | Roche cobas | 2,580 cps/mL | HBV PCR | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Abdominal pain; Itching; Depression | Additional Testing | ALT: 57; AST: 26; Bilirubin: 48.9 umol/L; Serum Creatinine: 1.02 mg/dL | |||||||||||||||||||
| DLS14-06950 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 1.00 | $55.00 | 61 Y | F | Asian | < -70C | 10-Jul-14 | Roche cobas | 29,100 IU/mL | HBV PCR | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice; Sleep disturbances | Additional Testing | ALT: 619; AST: 780; Bilirubin: 33.7 umol/L; Serum Creatinine: 0.67 mg/dL | Hepatitis Serology Result | HBsAg+ (Elisa) | |||||||||||||||||
| DLS14-06890 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 2.00 | $55.00 | 60 Y | F | Asian | < -70C | 10-Jul-14 | Aptima HBV Quant Assay | 918,157 IU/mL | 21-Jun-16 | Real-Time PCR | C | 18-Jul-14 | Aptima HBV Quant Assay | 5.96 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Decreased appetite; Fatigue; Abdominal pain; Depression | Additional Testing | ALT: 116; AST: 52; Bilirubin: 126.7 umol/L; Serum Creatinine: 0.7 mg/dL | 4-Jul-14 | Hepatitis Serology Result | N/A | ||||||||||
| DLS14-06905 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 2.00 | $55.00 | 29 Y | F | Asian | < -70C | 16-Sep-14 | Roche cobas | 26,100 IU/mL | HBV PCR | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice | Additional Testing | ALT: 166; AST: 175; Bilirubin: 146 umol/L; Serum Creatinine: 0.6 mg/dL | 9-Sep-14 | Hepatitis Serology Result | HBsAg + (Cobas) | 28-Aug-2014 | Roche Cobas | Positive | 13-Mar-2018 | ||||||||||||
| DLS14-06908 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 2.00 | $55.00 | 38 Y | F | Asian | < -70C | 13-Aug-14 | Aptima HBV Quant Assay | 222,377 IU/mL | 21-Jun-16 | Real-Time PCR | C | 14-Aug-14 | Aptima HBV Quant Assay | 5.35 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Fatigue; Abdominal pain; Jaundice | Additional Testing | ALT: 421; AST: 644; Bilirubin: 25.3 umol/L; Serum Creatinine: 0.74 mg/dL | 16-Jul-14 | Hepatitis Serology Result | N/A | ||||||||||
| DLS14-06960 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 3.00 | $55.00 | 41 Y | M | Asian | < -70C | 31-Jul-14 | Aptima HBV Quant Assay | 6,423 IU/mL | 21-Jun-16 | Real-Time PCR | C | 1-Aug-14 | Aptima HBV Quant Assay | 3.81 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Fatigue; Jaundice | Additional Testing | None | Hepatitis Serology Result | HBsAg +; Anti HCV + (Elisa) | 20-Jun-2014 | ||||||||||
| DLS14-07959 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 7.00 | $55.00 | 56 Y | M | Asian | < -70C | 13-Jan-15 | Aptima HBV Quant Assay | 341,051 IU/mL | 21-Jun-16 | Real-Time PCR | C | 22-Jan-15 | Aptima HBV Quant Assay | 5.53 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | Partial | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Jaundice; Flu-like Symptoms | Additional Testing | ALT: 118 U/L; AST: 31 U/L; Bilirubin: 30.6 umol/L; Serum Creatinine: 1.2 mg/dL | 4,5-Jan-2014 | Hepatitis Serology Result | HBsAg + (Cobas) | 5-Jan-2014 | Aptima HBV Quant Assay | Positive | 13-Mar-2018 | ||||||
| DLS14-07993 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 1.00 | $55.00 | 36 Y | F | Asian | < -70C | 31-Dec-14 | Aptima HBV Quant Assay | 14,773 IU/mL | 21-Jun-16 | Real-Time PCR | C | 22-Jan-15 | Aptima HBV Quant Assay | 4.17 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Decreased appetite; Jaundice | Additional Testing | ALT: 343 U/L; AST: 335 U/L; Bilirubin: 71.6 umol/L; Serum Creatinine: 59 umol/L | 15-Dec-14 | Hepatitis Serology Result | None | ||||||||||
| DLS14-08014 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 1.00 | $55.00 | 34 Y | F | Asian | < -70C | 07-Jan-15 | Roche cobas | 35,800 IU/mL | HBV PCR | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice | Additional Testing | ALT: 77 U/L; AST: 82 U/L; Bilirubin: 251.5 umol/L; Serum Creatinine: 0.6 mg/dL | 6-Jan-15 | Hepatitis Serology Result | None | |||||||||||||||
| DLS14-08016 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 1.00 | $55.00 | 34 Y | M | Asian | < -70C | 30-Dec-14 | Aptima HBV Quant Assay | 42,336 IU/mL | 21-Jun-16 | Real-Time PCR | C | 31-Dec-14 | Aptima HBV Quant Assay | 4.63 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Decreased appetite; Fatigue; Jaundice | Additional Testing | ALT: 197 U/L; AST: 210 U/L; Bilirubin: 87 umol/L; Serum Creatinine: 0.8 mg/dL | 19-Dec-14 | Hepatitis Serology Result | None | ||||||||||
| HEP5300-01 | Hepatitis B (HBV) | South Africa | Citrated Plasma | 1.00 | 126.00 | $75.00 | 25 Y | M | African | <-70C | 20-Sep-08 | Murex | Positive | HBV IgM | S/CO | 0.135 | OD Value | 4.012 | $75.00 | Sample Test Date | 27-Sep-08 | Treatment Status | Newly Diagnosed | Symptoms | None | Apparently Healthy | |||||||||||||||||||
| DLS14-31189 | Hepatitis B (HBV) | Italy | Serum | 1.00 | 4.00 | $55.00 | 53 Y | M | U/A | <-70C | 17-Nov-15 | Roche cobas | 229 IU/mL | HBV PCR | Roche Cobas | Positive | 13-Mar-2018 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | No | Symptoms | None | Additional Testing | Hepatitis Serology Result | HBsAg+ , HCV Ab- , HDV Ab- | Co-Infections | ||||||||||||||
| DLS14-07991 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 12.00 | $55.00 | 54 Y | M | Asian | <-70C | 22-May-15 | Roche cobas | 1,930 IU/mL | HBV PCR | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | |||||||||||||||||||||
| DLS14-08002 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 1.00 | $55.00 | 36 Y | M | Asian | <-70C | 22-May-15 | Roche cobas | 12,900 IU/mL | HBV PCR | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice | |||||||||||||||||||||
| DLS14-08011 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 9.00 | $55.00 | 25 Y | M | Asian | <-70C | 08-Jun-15 | Roche cobas | 3,250 IU/mL | HBV PCR | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice | |||||||||||||||||||||
| DLS14-21199 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 1.00 | $55.00 | 50 Y | M | Asian | <-70C | 02-Jul-15 | Aptima HBV Quant Assay | 225,982 IU/mL | 21-Jun-16 | Real-Time PCR | C | 9-Jul-15 | Aptima HBV Quant Assay | 5.35 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Decreased appetite; Fatigue; Jaundice | Additional Testing | N/A | Hepatitis Serology Result | N/A | |||||||||||
| DLS14-21206 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 6.00 | $55.00 | 29 Y | M | Asian | <-70C | 11-Jun-15 | Roche cobas | 121,000 IU/mL | HBV PCR | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice | |||||||||||||||||||||
| DLS14-21221 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 1.00 | $55.00 | 70 Y | M | Asian | <-70C | 15-Jun-15 | Aptima HBV Quant Assay | 286,995 IU/mL | 21-Jun-16 | Real-Time PCR | C | 1-Jul-15 | Aptima HBV Quant Assay | 5.46 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Decreased appetite; Fatigue; Jaundice | Additional Testing | N/A | Hepatitis Serology Result | N/A | |||||||||||
| DLS14-21241 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 6.00 | $55.00 | 30 Y | M | Asian | <-70C | 09-Jul-15 | Roche cobas | 41,400 IU/mL | HBV PCR | $55.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice | |||||||||||||||||||||
| DLS14-21277 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 4.00 | $55.00 | 36 Y | M | Asian | <-70C | 28-Aug-15 | Aptima HBV Quant Assay | 7,509 IU/mL | 21-Jun-16 | Real-Time PCR | C | 10-Sep-15 | Aptima HBV Quant Assay | 3.88 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Fatigue | Additional Testing | N/A | Hepatitis Serology Result | N/A | |||||||||||
| DLS14-21202 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 1.00 | $55.00 | 29 Y | M | Asian | <-70C | 18-Nov-15 | Aptima HBV Quant Assay | 208,990 IU/mL | 21-Jun-16 | Real-Time PCR | C | 26-Nov-15 | Aptima HBV Quant Assay | 5.32 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Additional Testing | N/A | Hepatitis Serology Result | N/A | |||||||||||
| DLS14-21231 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 1.00 | $55.00 | 31 Y | M | Asian | <-70C | 05-Oct-15 | Aptima HBV Quant Assay | 22,353 IU/mL | 21-Jun-16 | Real-Time PCR | C | 8-Oct-15 | Aptima HBV Quant Assay | 4.35 Log IU/mL | 21-Jun-16 | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Additional Testing | N/A | Hepatitis Serology Result | N/A | |||||||||||
| DLS14-21253 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 6.00 | $55.00 | 37 Y | M | Asian | <-70C | 18-Nov-15 | Roche cobas | 1,600,000 IU/mL | HBV PCR | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Symptoms | Decreased appetite; Fatigue; Jaundice | Additional testing | ALT: 545 U/L, AST: 181 U/L, Bilirubin: 96 umol/L | Hepatitis Serology Result | None | |||||||||||||||||||
| DLS14-21254 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 6.00 | $55.00 | 28 Y | F | Asian | <-70C | 18-Nov-15 | Roche cobas | 33,700 IU/mL | HBV PCR | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice | Additional Testing | ALT: 1332 U/L, AST: 910 U/L, Bilirubin: 104 umol/L | 06-Nov-2015 | Hepatitis Serology Result | None | ||||||||||||||||
| DLS14-21268 | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 2.00 | $55.00 | 32 Y | F | Asian | <-70C | 09-Dec-15 | Roche cobas | 6,790,000 IU/mL | HBV PCR | $55.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue | Additional testing | ALT: 715 U/L, AST: 349 U/L, Bilirubin: 7.6 umol/L, Creatinine: 75 umol/L | 28-Nov-2015 | Hepatitis Serology Result | None | ||||||||||||||||
| DLS17-050034-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 6.00 | $150.00 | 51 Y | M | Asian | <-70C | 27-Dec-17 | Roche Cobas Taqman | 7,170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 20-Dec-17 | $150.00 | Initial Date of Diagnosis | 20-Dec-17 | Additional Testing | ALT: 227 U/L | AST: 412 U/L | ALP: 160 U/L | Bilirubin: 28.2 umol/L | Creatinine: 87 umol/L | Chronic Hepatitis B | 20-Dec-17 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050034-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 8.00 | $150.00 | 51 Y | M | Asian | <-70C | 27-Dec-17 | Roche Cobas Taqman | 7,170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 20-Dec-17 | $150.00 | Initial Date of Diagnosis | 20-Dec-17 | Additional Testing | ALT: 227 U/L | AST: 412 U/L | ALP: 160 U/L | Bilirubin: 28.2 umol/L | Creatinine: 87 umol/L | Chronic Hepatitis B | 20-Dec-17 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050035-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 6.00 | $150.00 | 71 Y | F | Asian | <-70C | 27-Dec-17 | Roche Cobas Taqman | 911,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 23-Dec-17 | $150.00 | Initial Date of Diagnosis | 2010 | Additional Testing | ALT: 193 U/L | AST: 140 U/L | Bilirubin: 12.8 umol/L | Creatinine: 60 umol/L | Chronic Hepatitis B | 23-Dec-17 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050035-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 7.00 | $150.00 | 71 Y | F | Asian | <-70C | 27-Dec-17 | Roche Cobas Taqman | 911,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 23-Dec-17 | $150.00 | Initial Date of Diagnosis | 2010 | Additional Testing | ALT: 193 U/L | AST: 140 U/L | Bilirubin: 12.8 umol/L | Creatinine: 60 umol/L | Chronic Hepatitis B | 23-Dec-17 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050042-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 8.00 | $150.00 | 48 Y | M | Asian | <-70C | 05-Jun-18 | Roche Cobas Taqman | 7,170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 28-May-18 | $150.00 | Initial Date of Diagnosis | 2010 | Additional Testing | ALT: 544 U/L | AST: 834 U/L | Bilirubin: 39 umol/L | Creatinine: 68 umol/L | Chronic Hepatitis B | 28-May-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050042-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 9.00 | $150.00 | 48 Y | M | Asian | <-70C | 05-Jun-18 | Roche Cobas Taqman | 7,170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 28-May-18 | $150.00 | Initial Date of Diagnosis | 2010 | Additional Testing | ALT: 544 U/L | AST: 834 U/L | Bilirubin: 39 umol/L | Creatinine: 68 umol/L | Chronic Hepatitis B | 28-May-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050044-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 6.00 | $150.00 | 44 Y | M | Asian | <-70C | 26-Jan-18 | Roche Cobas Taqman | 7,480,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 5-Jan-18 | $150.00 | Initial Date of Diagnosis | 5-Jan-18 | Additional Testing | ALT: 551 U/L | AST: 1296 U/L | Bilirubin: 55.2 umol/L | Creatinine: 81 umol/L | Chronic Hepatitis B | 19-Jan-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050044-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 6.00 | $150.00 | 44 Y | M | Asian | <-70C | 26-Jan-18 | Roche Cobas Taqman | 7,480,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 5-Jan-18 | $150.00 | Initial Date of Diagnosis | 5-Jan-18 | Additional Testing | ALT: 551 U/L | AST: 1296 U/L | Bilirubin: 55.2 umol/L | Creatinine: 81 umol/L | Chronic Hepatitis B | 19-Jan-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050045-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 7.00 | $150.00 | 31 Y | M | Asian | <-70C | 19-Jan-18 | Roche Cobas Taqman | 22,400,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 15-Jan-18 | $150.00 | Initial Date of Diagnosis | 15-Jan-18 | Additional Testing | ALT: 665 U/L | AST: 1710 U/L | ALP: 107 U/L | Bilirubin: 47.8 umol/L | Creatinine: 97 umol/L | Hepatitis B | 15-Jan-18 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050045-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 6.00 | $150.00 | 31 Y | M | Asian | <-70C | 19-Jan-18 | Roche Cobas Taqman | 22,400,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 15-Jan-18 | $150.00 | Initial Date of Diagnosis | 15-Jan-18 | Additional Testing | ALT: 665 U/L | AST: 1710 U/L | ALP: 107 U/L | Bilirubin: 47.8 umol/L | Creatinine: 97 umol/L | Hepatitis B | 15-Jan-18 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050046-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 8.00 | $150.00 | 37 Y | M | Asian | <-70C | 26-Jan-18 | Roche Cobas Taqman | 18,100 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 16-Jan-18 | $150.00 | Initial Date of Diagnosis | 16-Jan-18 | Additional Testing | ALT: 900 U/L | AST: 1500 U/L | Bilirubin: 328.7 umol/L | Creatinine: 80 umol/L | Chronic Hepatitis B | 11-Jan-18 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050046-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 7.00 | $150.00 | 37 Y | M | Asian | <-70C | 26-Jan-18 | Roche Cobas Taqman | 18,100 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 16-Jan-18 | $150.00 | Initial Date of Diagnosis | 16-Jan-18 | Additional Testing | ALT: 900 U/L | AST: 1500 U/L | Bilirubin: 328.7 umol/L | Creatinine: 80 umol/L | Chronic Hepatitis B | 11-Jan-18 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050048-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 0.75 | 8.00 | $150.00 | 30 Y | M | Asian | <-70C | 04-Jun-18 | Roche Cobas Taqman | 5,050,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 23-May-18 | $150.00 | Initial Date of Diagnosis | 2016 | Additional Testing | ALT: 2355 U/L | AST: 1514 U/L | Bilirubin: 93.6 umol/L | Creatinine: 71 umol/L | Hepatitis B | 23-May-18 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050048-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 8.00 | $150.00 | 30 Y | M | Asian | <-70C | 04-Jun-18 | Roche Cobas Taqman | 5,050,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 23-May-18 | $150.00 | Initial Date of Diagnosis | 2016 | Additional Testing | ALT: 2355 U/L | AST: 1514 U/L | Bilirubin: 93.6 umol/L | Creatinine: 71 umol/L | Hepatitis B | 23-May-18 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050049-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 9.00 | $150.00 | 62 Y | M | Asian | <-70C | 26-Jan-18 | Roche Cobas Taqman | 102,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 18-Jan-18 | $150.00 | Initial Date of Diagnosis | 18-Jan-18 | Additional Testing | ALT: 104 U/L | AST: 272 U/L | Bilirubin: 173 umol/L | Creatinine: 53 umol/L | Chronic Hepatitis B | 18-Jan-18 | Current Signs and Symptoms | Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050051-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 9.00 | $150.00 | 59 Y | M | Asian | <-70C | 26-Jan-18 | Roche Cobas Taqman | 37,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 19-Jan-18 | $150.00 | Initial Date of Diagnosis | 2016 | Additional Testing | ALT: 3350 U/L | AST: 1762 U/L | Bilirubin: 61.1 umol/L | Creatinine: 98 umol/L | Chronic Hepatitis B | 19-Jan-18 | Current Signs and Symptoms | Abdominal pain; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050051-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 8.00 | $150.00 | 59 Y | M | Asian | <-70C | 26-Jan-18 | Roche Cobas Taqman | 37,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 19-Jan-18 | $150.00 | Initial Date of Diagnosis | 2016 | Additional Testing | ALT: 3350 U/L | AST: 1762 U/L | Bilirubin: 61.1 umol/L | Creatinine: 98 umol/L | Chronic Hepatitis B | 19-Jan-18 | Current Signs and Symptoms | Abdominal pain; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050052-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 7.00 | $150.00 | 30 Y | F | Asian | <-70C | 26-Jan-18 | Roche Cobas Taqman | 1,240,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 17-Jan-18 | $150.00 | Initial Date of Diagnosis | 17-Jan-18 | Additional Testing | ALT: 337 U/L | AST: 490 U/L | Bilirubin: 14 umol/L | Creatinine: 73 umol/L | Chronic Hepatitis B | 17-Jan-18 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050053-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 0.90 | 5.00 | $150.00 | 31 Y | M | Asian | <-70C | 10-Jan-18 | Roche Cobas Taqman | 313,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 2-Jan-18 | $150.00 | Initial Date of Diagnosis | 2-Jan-18 | Additional Testing | ALT: 153 U/L | AST: 503 U/L | Bilirubin: 17.3 umol/L | Creatinine: 75 umol/L | Acute Hepatitis B | 4-Jan-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050053-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 7.00 | $150.00 | 31 Y | M | Asian | <-70C | 10-Jan-18 | Roche Cobas Taqman | 313,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 2-Jan-18 | $150.00 | Initial Date of Diagnosis | 2-Jan-18 | Additional Testing | ALT: 153 U/L | AST: 503 U/L | Bilirubin: 17.3 umol/L | Creatinine: 75 umol/L | Acute Hepatitis B | 4-Jan-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050054-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 7.00 | $150.00 | 35 Y | F | Asian | <-70C | 27-Dec-17 | Roche Cobas Taqman | 774,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 18-Dec-17 | $150.00 | Initial Date of Diagnosis | 18-Dec-17 | Additional Testing | ALT: 110 U/L | AST: 322 U/L | Bilirubin: 25.7 umol/L | Creatinine: 72 umol/L | Acute Hepatitis B | 18-Dec-17 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050054-S | Hepatitis B (HBV) | Vietnam | Serum | 0.90 | 7.00 | $150.00 | 35 Y | F | Asian | <-70C | 27-Dec-17 | Roche Cobas Taqman | 774,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 18-Dec-17 | $150.00 | Initial Date of Diagnosis | 18-Dec-17 | Additional Testing | ALT: 110 U/L | AST: 322 U/L | Bilirubin: 25.7 umol/L | Creatinine: 72 umol/L | Acute Hepatitis B | 18-Dec-17 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050056-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 8.00 | $150.00 | 54 Y | M | Asian | <-70C | 29-Dec-17 | Roche Cobas Taqman | 3,300,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 25-Dec-17 | $150.00 | Initial Date of Diagnosis | 2000 | Additional Testing | ALT: 59 U/L | AST: 126 U/L | Bilirubin: 431.4 umol/L | Creatinine: 95 umol/L | Hepatitis B | 25-Dec-17 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050058-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 6.00 | $150.00 | 57 Y | M | Asian | <-70C | 19-Jan-18 | Roche Cobas Taqman | 177,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 16-Jan-18 | $150.00 | Initial Date of Diagnosis | 2008 | Additional Testing | ALT: 100 U/L | AST: 202 U/L | Bilirubin: 10.2 umol/L | Creatinine: 63 umol/L | Chronic Hepatitis B | 16-Jan-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050058-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 6.00 | $150.00 | 57 Y | M | Asian | <-70C | 19-Jan-18 | Roche Cobas Taqman | 177,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 16-Jan-18 | $150.00 | Initial Date of Diagnosis | 2008 | Additional Testing | ALT: 100 U/L | AST: 202 U/L | Bilirubin: 10.2 umol/L | Creatinine: 63 umol/L | Chronic Hepatitis B | 16-Jan-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050059-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 8.00 | $150.00 | 47 Y | M | Asian | <-70C | 27-Dec-17 | Roche Cobas Taqman | 7,170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | None | $150.00 | Initial Date of Diagnosis | 1997 | Additional Testing | ALT: 693 U/L | AST: 1084 U/L | Bilirubin: 16.5 umol/L | Creatinine: 94 umol/L | Chronic Hepatitis B | 20-Dec-17 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue | Co-Infections | None | ||||||||||||||||||
| DLS17-050059-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 6.00 | $150.00 | 47 Y | M | Asian | <-70C | 27-Dec-17 | Roche Cobas Taqman | 7,170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | None | $150.00 | Initial Date of Diagnosis | 1997 | Additional Testing | ALT: 693 U/L | AST: 1084 U/L | Bilirubin: 16.5 umol/L | Creatinine: 94 umol/L | Chronic Hepatitis B | 20-Dec-17 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue | Co-Infections | None | ||||||||||||||||||
| DLS17-050061-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 2.00 | $150.00 | 33 Y | M | Asian | <-70C | 02-Aug-18 | Roche Cobas Taqman | 4,170,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 28-Jun-18 | $150.00 | Initial Date of Diagnosis | 18-Jun | Additional Testing | ALT: 537 U/L | AST: 107 U/L | Bilirubin: 13.2 umol/L | Creatinine: 62 umol/L | Chronic Hepatitis B | 30-Jun-18 | Current Signs and Symptoms | Abdominal pain; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050061-S | Hepatitis B (HBV) | Vietnam | Serum | 0.90 | 4.00 | $150.00 | 33 Y | M | Asian | <-70C | 02-Aug-18 | Roche Cobas Taqman | 4,170,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 28-Jun-18 | $150.00 | Initial Date of Diagnosis | 18-Jun | Additional Testing | ALT: 537 U/L | AST: 107 U/L | Bilirubin: 13.2 umol/L | Creatinine: 62 umol/L | Chronic Hepatitis B | 30-Jun-18 | Current Signs and Symptoms | Abdominal pain; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050063-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 8.00 | $150.00 | 42 Y | M | Asian | <-70C | 05-Jun-18 | Roche Cobas Taqman | 556,000 IU/mL | HBV DNA | Hepatitis Serology Result | HCV Ab + ; HBsAg + | 17-May-18 | $150.00 | Initial Date of Diagnosis | 17-May-18 | Additional Testing | ALT: 227 U/L | AST: 114 U/L | Bilirubin: 117 umol/L | Creatinine: 73 umol/L | Hepatitis B and C | 25-May-18 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | HCV Ab+ ; HCV RNA- | |||||||||||||||||
| DLS17-050063-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 8.00 | $150.00 | 42 Y | M | Asian | <-70C | 05-Jun-18 | Roche Cobas Taqman | 556,000 IU/mL | HBV DNA | Hepatitis Serology Result | HCV Ab + ; HBsAg + | 17-May-18 | $150.00 | Initial Date of Diagnosis | 17-May-18 | Additional Testing | ALT: 227 U/L | AST: 114 U/L | Bilirubin: 117 umol/L | Creatinine: 73 umol/L | Hepatitis B and C | 25-May-18 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | HCV Ab+ ; HCV RNA- | |||||||||||||||||
| DLS17-050067-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 8.00 | $150.00 | 70 Y | F | Asian | <-70C | 19-Jan-18 | Roche Cobas Taqman | 97,200 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 15-Jan-18 | $150.00 | Initial Date of Diagnosis | 1998 | Additional Testing | ALT: 227 U/L | AST: 186 U/L | Bilirubin: 10.9 umol/L | Creatinine: 66 umol/L | Chronic Hepatitis B | 18-Jan-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050068-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 6.00 | $150.00 | 60 Y | F | Asian | <-70C | 31-Jul-18 | Roche Cobas Taqman | 2,050 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; HBeAb + ; HBcTotal + ; | 25-Jul-18 | $150.00 | Initial Date of Diagnosis | 1998 | Additional Testing | ALT: 74 U/L | AST: 155 U/L | Bilirubin: 44.1 umol/L | Creatinine: 54 umol/L | Chronic Hepatitis B | 25-Jul-18 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050068-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 6.00 | $150.00 | 60 Y | F | Asian | <-70C | 31-Jul-18 | Roche Cobas Taqman | 2,050 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; HBeAb + ; HBcTotal + ; | 25-Jul-18 | $150.00 | Initial Date of Diagnosis | 1998 | Additional Testing | ALT: 74 U/L | AST: 155 U/L | Bilirubin: 44.1 umol/L | Creatinine: 54 umol/L | Chronic Hepatitis B | 25-Jul-18 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050071-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 8.00 | $150.00 | 55 Y | M | Asian | <-70C | 04-Jun-18 | Roche Cobas Taqman | 34,500,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; HBeAb + ; HBcTotal + ; | 28-May-18 | $150.00 | Initial Date of Diagnosis | 25-May-18 | Additional Testing | ALT: 683 U/L | AST: 241 U/L | Bilirubin: 39 umol/L | Creatinine: 68 umol/L | Chronic Hepatitis B | 31-May-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050071-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 6.00 | $150.00 | 55 Y | M | Asian | <-70C | 04-Jun-18 | Roche Cobas Taqman | 34,500,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; HBeAb + ; HBcTotal + ; | 28-May-18 | $150.00 | Initial Date of Diagnosis | 25-May-18 | Additional Testing | ALT: 683 U/L | AST: 241 U/L | Bilirubin: 39 umol/L | Creatinine: 68 umol/L | Chronic Hepatitis B | 31-May-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050075-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 4.00 | $150.00 | 59 Y | M | Asian | <-70C | 03-Aug-18 | Roche Cobas Taqman | 737,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 27-Jul-18 | $150.00 | Initial Date of Diagnosis | 2014 | Additional Testing | ALT: 54 U/L | AST: 105 U/L | Bilirubin: 71.4 umol/L | Creatinine: 179 umol/L | Chronic Hepatitis B | 26-Jul-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050075-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 8.00 | $150.00 | 59 Y | M | Asian | <-70C | 03-Aug-18 | Roche Cobas Taqman | 737,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 27-Jul-18 | $150.00 | Initial Date of Diagnosis | 2014 | Additional Testing | ALT: 54 U/L | AST: 105 U/L | Bilirubin: 71.4 umol/L | Creatinine: 179 umol/L | Chronic Hepatitis B | 26-Jul-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050077-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 6.00 | $150.00 | 62 Y | M | Asian | <-70C | 28-May-18 | Roche Cobas Taqman | 663,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + HBeAg - | 9-May-18 | $150.00 | Initial Date of Diagnosis | 2008 | Additional Testing | ALT: 306 U/L | AST: 203 U/L | Bilirubin: 38.2 umol/L | Creatinine: 76 umol/L | Chronic Hepatitis B | 15-May-18 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050077-S | Hepatitis B (HBV) | Vietnam | Serum | 0.75 | 7.00 | $150.00 | 62 Y | M | Asian | <-70C | 28-May-18 | Roche Cobas Taqman | 663,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + HBeAg - | 9-May-18 | $150.00 | Initial Date of Diagnosis | 2008 | Additional Testing | ALT: 306 U/L | AST: 203 U/L | Bilirubin: 38.2 umol/L | Creatinine: 76 umol/L | Chronic Hepatitis B | 15-May-18 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050081-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 5.00 | $150.00 | 73 Y | M | Asian | <-70C | 29-Dec-17 | Roche Cobas Taqman | 2,280 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 29-Dec-17 | $150.00 | Initial Date of Diagnosis | 18-Dec-17 | Additional Testing | ALT: 100 U/L | AST: 75 U/L | Bilirubin: 18.3 umol/L | Creatinine: 72 umol/L | Hepatitis B | 25-Dec-17 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050081-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 6.00 | $150.00 | 73 Y | M | Asian | <-70C | 29-Dec-17 | Roche Cobas Taqman | 2,280 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 29-Dec-17 | $150.00 | Initial Date of Diagnosis | 18-Dec-17 | Additional Testing | ALT: 100 U/L | AST: 75 U/L | Bilirubin: 18.3 umol/L | Creatinine: 72 umol/L | Hepatitis B | 25-Dec-17 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050083-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 6.00 | $150.00 | 29 Y | M | Asian | <-70C | 25-May-18 | Roche Cobas Taqman | 17,800 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 17-May-18 | $150.00 | Initial Date of Diagnosis | 17-May-18 | Additional Testing | ALT: 175 U/L | AST: 244 U/L | Bilirubin: 300 umol/L | Creatinine: 92 umol/L | Chronic Hepatitis B | 21-May-18 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050084-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 7.00 | $150.00 | 34 Y | M | Asian | <-70C | 27-Dec-17 | Roche Cobas Taqman | 43,900 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 9-Nov-17 | $150.00 | Initial Date of Diagnosis | 9-Nov-17 | Additional Testing | ALT: 89 U/L | AST: 127 U/L | Bilirubin: 127 umol/L | Creatinine: 60 umol/L | Hepatitis B | 26-Dec-17 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050084-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 7.00 | $150.00 | 34 Y | M | Asian | <-70C | 27-Dec-17 | Roche Cobas Taqman | 43,900 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 9-Nov-17 | $150.00 | Initial Date of Diagnosis | 9-Nov-17 | Additional Testing | ALT: 89 U/L | AST: 127 U/L | Bilirubin: 127 umol/L | Creatinine: 60 umol/L | Hepatitis B | 26-Dec-17 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050090-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 8.00 | $150.00 | 41 Y | M | Asian | <-70C | 02-Aug-18 | Roche Cobas Taqman | 3,250,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 13-Jul-18 | $150.00 | Initial Date of Diagnosis | 13-Jul-18 | Additional Testing | ALT: 138 U/L | AST: 25 U/L | Bilirubin: 200 umol/L | Creatinine: 67 umol/L | Chronic Hepatitis B | 25-Jul-18 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050090-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 8.00 | $150.00 | 41 Y | M | Asian | <-70C | 02-Aug-18 | Roche Cobas Taqman | 3,250,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 13-Jul-18 | $150.00 | Initial Date of Diagnosis | 13-Jul-18 | Additional Testing | ALT: 138 U/L | AST: 25 U/L | Bilirubin: 200 umol/L | Creatinine: 67 umol/L | Chronic Hepatitis B | 25-Jul-18 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050091-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 8.00 | $150.00 | 28 Y | M | Asian | <-70C | 25-May-18 | Roche Cobas Taqman | 7,170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBeAg +; HBeAb - | 23-May-18 | $150.00 | Initial Date of Diagnosis | 2014 | Additional Testing | ALT: 657 U/L | AST: 343 U/L | Bilirubin: 86 umol/L | Creatinine: 82 umol/L | Chronic Hepatitis B | 21-May-18 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050091-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 7.00 | $150.00 | 28 Y | M | Asian | <-70C | 25-May-18 | Roche Cobas Taqman | 7,170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBeAg +; HBeAb - | 23-May-18 | $150.00 | Initial Date of Diagnosis | 2014 | Additional Testing | ALT: 657 U/L | AST: 343 U/L | Bilirubin: 86 umol/L | Creatinine: 82 umol/L | Chronic Hepatitis B | 21-May-18 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050103-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 8.00 | $150.00 | 48 Y | M | Asian | <-70C | 05-Jun-18 | Roche Cobas Taqman | 4,180,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg +; HBcTotal + | 25-May-18 | $150.00 | Initial Date of Diagnosis | 2013 | Additional Testing | ALT: 73 U/L | AST: 66 U/L | Bilirubin: 70.4 umol/L | Creatinine: 69 umol/L | Chronic Hepatitis B | 25-May-18 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050103-S | Hepatitis B (HBV) | Vietnam | Serum | 0.90 | 7.00 | $150.00 | 48 Y | M | Asian | <-70C | 05-Jun-18 | Roche Cobas Taqman | 4,180,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg +; HBcTotal + | 25-May-18 | $150.00 | Initial Date of Diagnosis | 2013 | Additional Testing | ALT: 73 U/L | AST: 66 U/L | Bilirubin: 70.4 umol/L | Creatinine: 69 umol/L | Chronic Hepatitis B | 25-May-18 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050106-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 10.00 | $150.00 | 78 Y | M | Asian | <-70C | 26-Jan-18 | Roche Cobas Taqman | 651,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 19-Jan-18 | $150.00 | Initial Date of Diagnosis | 17-Feb | Additional Testing | ALT: 82 U/L | AST: 34 U/L | Bilirubin: 68 umol/L | Creatinine: 269 umol/L | Chronic Hepatitis B | 25-Jan-18 | Current Signs and Symptoms | Abdominal pain; Dark urine; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050109-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 10.00 | $150.00 | 34 Y | M | Asian | <-70C | 27-Dec-17 | Roche Cobas Taqman | 7,170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 2003 | $150.00 | Initial Date of Diagnosis | 2003 | Additional Testing | ALT: 881 U/L | AST: 606 U/L | Bilirubin: 140.4 umol/L | Creatinine: 72 umol/L | Chronic Hepatitis B | 22-Dec-17 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050109-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 8.00 | $150.00 | 34 Y | M | Asian | <-70C | 27-Dec-17 | Roche Cobas Taqman | 7,170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 2003 | $150.00 | Initial Date of Diagnosis | 2003 | Additional Testing | ALT: 881 U/L | AST: 606 U/L | Bilirubin: 140.4 umol/L | Creatinine: 72 umol/L | Chronic Hepatitis B | 22-Dec-17 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050121-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 6.00 | $150.00 | 27 Y | M | Asian | <-70C | 05-Jun-18 | Roche Cobas Taqman | 15,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; HBeAg + ; HBeAb - | 30-May-18 | $150.00 | Initial Date of Diagnosis | 2015 | Additional Testing | ALT: 697 U/L | AST: 374 U/L | Bilirubin: 62 umol/L | Creatinine: 67 umol/L | Chronic Hepatitis B | 30-May-18 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050121-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 6.00 | $150.00 | 27 Y | M | Asian | <-70C | 05-Jun-18 | Roche Cobas Taqman | 15,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; HBeAg + ; HBeAb - | 30-May-18 | $150.00 | Initial Date of Diagnosis | 2015 | Additional Testing | ALT: 697 U/L | AST: 374 U/L | Bilirubin: 62 umol/L | Creatinine: 67 umol/L | Chronic Hepatitis B | 30-May-18 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050124-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 6.00 | $150.00 | 68 Y | M | Asian | <-70C | 14-Mar-18 | Roche Cobas Taqman | 74,400 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 9-Mar-18 | $150.00 | Initial Date of Diagnosis | 1998 | Additional Testing | ALT: 418 U/L | AST: 269 U/L | Bilirubin: 20.6 umol/L | Creatinine: 99 umol/L | Chronic Hepatitis B | 8-Mar-18 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050124-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 10.00 | $150.00 | 68 Y | M | Asian | <-70C | 14-Mar-18 | Roche Cobas Taqman | 74,400 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 9-Mar-18 | $150.00 | Initial Date of Diagnosis | 1998 | Additional Testing | ALT: 418 U/L | AST: 269 U/L | Bilirubin: 20.6 umol/L | Creatinine: 99 umol/L | Chronic Hepatitis B | 8-Mar-18 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050130-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 4.00 | $150.00 | 29 Y | F | Asian | <-70C | 17-Apr-18 | Roche Cobas Taqman | 2,600 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; HBeAg + ; HBcIgG + | 30-Mar-2018 | 3-Apr-2018 | $150.00 | Initial Date of Diagnosis | 30-Mar-18 | Additional Testing | ALT: 479 U/L | AST: 178 U/L | Bilirubin: 25.8 umol/L | Creatinine: 64 umol/L | Chronic Hepatitis B | 10-Apr-18 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050130-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 6.00 | $150.00 | 29 Y | F | Asian | <-70C | 17-Apr-18 | Roche Cobas Taqman | 2,600 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; HBeAg + ; HBcIgG + | 30-Mar-2018 | 3-Apr-2018 | $150.00 | Initial Date of Diagnosis | 30-Mar-18 | Additional Testing | ALT: 479 U/L | AST: 178 U/L | Bilirubin: 25.8 umol/L | Creatinine: 64 umol/L | Chronic Hepatitis B | 10-Apr-18 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050132-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 2.00 | $150.00 | 35 Y | M | Asian | <-70C | 17-Apr-18 | Roche Cobas Taqman | 170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; Anti HBcIgG + | 3-Apr-18 | $150.00 | Initial Date of Diagnosis | 3-Apr-18 | Additional Testing | ALT: 1464 U/L | AST: 971 U/L | Bilirubin: 66 umol/L | Creatinine: 95 umol/L | Acute Hepatitis B | 30-Mar-18 | Current Signs and Symptoms | Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050134-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 6.00 | $150.00 | 51 Y | F | Asian | <-70C | 17-Apr-18 | Roche Cobas Taqman | 3,390 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 27-Mar-18 | $150.00 | Initial Date of Diagnosis | 2018 | Additional Testing | ALT: 2108 U/L | AST: 1668 U/L | Bilirubin: 126.6 umol/L | Creatinine: 55 umol/L | Acute Hepatitis B | 23-Mar-18 | Current Signs and Symptoms | Fatigue; Fever | Co-Infections | None | |||||||||||||||||
| DLS17-050134-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 7.00 | $150.00 | 51 Y | F | Asian | <-70C | 17-Apr-18 | Roche Cobas Taqman | 3,390 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 27-Mar-18 | $150.00 | Initial Date of Diagnosis | 2018 | Additional Testing | ALT: 2108 U/L | AST: 1668 U/L | Bilirubin: 126.6 umol/L | Creatinine: 55 umol/L | Acute Hepatitis B | 23-Mar-18 | Current Signs and Symptoms | Fatigue; Fever | Co-Infections | None | |||||||||||||||||
| DLS17-050135-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 5.00 | $150.00 | 27 Y | F | Asian | <-70C | 17-Apr-18 | Roche Cobas Taqman | 7,350 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; HBeAg + ; | 6-Apr-18 | $150.00 | Initial Date of Diagnosis | 6-Apr-18 | Additional Testing | ALT: 1045 U/L | AST: 2374 U/L | 6-Apr-2018 | Bilirubin: 91 umol/L | Creatinine: 52 umol/L | Acute Hepatitis B | 4-Apr-18 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050135-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 6.00 | $150.00 | 27 Y | F | Asian | <-70C | 17-Apr-18 | Roche Cobas Taqman | 7,350 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; HBeAg + ; | 6-Apr-18 | $150.00 | Initial Date of Diagnosis | 6-Apr-18 | Additional Testing | ALT: 1045 U/L | AST: 2374 U/L | 6-Apr-2018 | Bilirubin: 91 umol/L | Creatinine: 52 umol/L | Acute Hepatitis B | 4-Apr-18 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050136-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 6.00 | $150.00 | 57 Y | F | Asian | <-70C | 09-Mar-18 | Roche Cobas Taqman | 4,660 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 28-Feb-18 | $150.00 | Initial Date of Diagnosis | 18-Feb | Additional Testing | ALT: 86 U/L | AST: 69 U/L | Bilirubin: 42.9 umol/L | Creatinine: 62 umol/L | Chronic Hepatitis B | 8-Mar-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050136-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 7.00 | $150.00 | 57 Y | F | Asian | <-70C | 09-Mar-18 | Roche Cobas Taqman | 4,660 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 28-Feb-18 | $150.00 | Initial Date of Diagnosis | 18-Feb | Additional Testing | ALT: 86 U/L | AST: 69 U/L | Bilirubin: 42.9 umol/L | Creatinine: 62 umol/L | Chronic Hepatitis B | 8-Mar-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050138-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.25 | 6.00 | $150.00 | 46 Y | F | Asian | <-70C | 24-Apr-18 | Roche Cobas Taqman | 57,600,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBeAb + ;HBeAg + ; | 17-Apr-18 | $150.00 | Initial Date of Diagnosis | 2008 | Additional Testing | ALT: 1075 U/L | AST: 740 U/L | Bilirubin: 15.6 umol/L | Creatinine: 59 umol/L | Chronic Hepatitis B | 10-Apr-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050138-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 8.00 | $150.00 | 46 Y | F | Asian | <-70C | 24-Apr-18 | Roche Cobas Taqman | 57,600,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBeAb + ;HBeAg + ; | 17-Apr-18 | $150.00 | Initial Date of Diagnosis | 2008 | Additional Testing | ALT: 1075 U/L | AST: 740 U/L | Bilirubin: 15.6 umol/L | Creatinine: 59 umol/L | Chronic Hepatitis B | 10-Apr-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050139-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 2.00 | $150.00 | 33 Y | M | Asian | <-70C | 24-Apr-18 | Roche Cobas Taqman | 7,170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; HBeAb + ; HBeAg - ; | 19-Apr-18 | $150.00 | Initial Date of Diagnosis | 2012 | Additional Testing | ALT: 48 U/L | AST: 34 U/L | Bilirubin: 4.9 umol/L | Creatinine: 85 umol/L | Chronic Hepatitis B | 9-Apr-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050139-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 8.00 | $150.00 | 33 Y | M | Asian | <-70C | 24-Apr-18 | Roche Cobas Taqman | 7,170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; HBeAb + ; HBeAg - ; | 19-Apr-18 | $150.00 | Initial Date of Diagnosis | 2012 | Additional Testing | ALT: 48 U/L | AST: 34 U/L | Bilirubin: 4.9 umol/L | Creatinine: 85 umol/L | Chronic Hepatitis B | 9-Apr-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050144-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 4.00 | $150.00 | 51 Y | F | Asian | <-70C | 17-Apr-18 | Roche Cobas Taqman | 94,800,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; ;HBeAg - ;HBcIgG + ; Anti HBC + | 9-Apr-2018 | 12-Apr-2018 | $150.00 | Initial Date of Diagnosis | 9-Apr-18 | Additional Testing | ALT: 1335 U/L | AST: 781 U/L | ALP: 150 U/L | Bilirubin: 51 umol/L | Creatinine: 55 umol/L | Acute Hepatitis B | 10-Apr-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050146-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 8.00 | $150.00 | 45 Y | M | Asian | <-70C | 19-Jan-18 | Roche Cobas Taqman | 7,170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 9-Jan-18 | $150.00 | Initial Date of Diagnosis | 9-Jan-18 | Additional Testing | ALT: 300 U/L | AST: 673 U/L | ALP: 101 U/L | Bilirubin: 21.3 umol/L | Creatinine: 87 umol/L | Chronic Hepatitis B | 9-Jan-18 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050146-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 5.00 | $150.00 | 45 Y | M | Asian | <-70C | 19-Jan-18 | Roche Cobas Taqman | 7,170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 9-Jan-18 | $150.00 | Initial Date of Diagnosis | 9-Jan-18 | Additional Testing | ALT: 300 U/L | AST: 673 U/L | ALP: 101 U/L | Bilirubin: 21.3 umol/L | Creatinine: 87 umol/L | Chronic Hepatitis B | 9-Jan-18 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050148-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 9.00 | $150.00 | 42 Y | M | Asian | <-70C | 14-Mar-18 | Roche Cobas Taqman | 4,210 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 9-Mar-18 | $150.00 | Initial Date of Diagnosis | 2008 | Additional Testing | ALT: 361 U/L | AST: 192 U/L | Bilirubin: 513 umol/L | Creatinine: 72 umol/L | Cirrhosis and Hepatitis B | 6-Mar-18 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | Cirrhosis | |||||||||||||||||
| DLS17-050148-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 10.00 | $150.00 | 42 Y | M | Asian | <-70C | 14-Mar-18 | Roche Cobas Taqman | 4,210 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 9-Mar-18 | $150.00 | Initial Date of Diagnosis | 2008 | Additional Testing | ALT: 361 U/L | AST: 192 U/L | Bilirubin: 513 umol/L | Creatinine: 72 umol/L | Cirrhosis and Hepatitis B | 6-Mar-18 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | Cirrhosis | |||||||||||||||||
| DLS17-050153-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.25 | 4.00 | $150.00 | 37 Y | M | Asian | <-70C | 17-Apr-18 | Roche Cobas Taqman | 31,600,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 7-Apr-18 | $150.00 | Initial Date of Diagnosis | 2014 | Additional Testing | ALT: 317 U/L | AST: 139 U/L | Bilirubin: 163 umol/L | Creatinine: 102 umol/L | Chronic Hepatitis B | 7-Apr-18 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050153-S | Hepatitis B (HBV) | Vietnam | Serum | 1.25 | 5.00 | $150.00 | 37 Y | M | Asian | <-70C | 17-Apr-18 | Roche Cobas Taqman | 31,600,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 7-Apr-18 | $150.00 | Initial Date of Diagnosis | 2014 | Additional Testing | ALT: 317 U/L | AST: 139 U/L | Bilirubin: 163 umol/L | Creatinine: 102 umol/L | Chronic Hepatitis B | 7-Apr-18 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050155-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 8.00 | $150.00 | 60 Y | M | Asian | <-70C | 19-Apr-18 | Roche Cobas Taqman | 170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; HBeAg - ; HBcIgM - | 29-Mar-18 | $150.00 | Initial Date of Diagnosis | 10-Mar-18 | Additional Testing | ALT: 877 U/L | AST: 1094 U/L | Bilirubin: 135 umol/L | Creatinine: 69 umol/L | Chronic Hepatitis B | 13-Apr-18 | Current Signs and Symptoms | Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050155-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 8.00 | $150.00 | 60 Y | M | Asian | <-70C | 19-Apr-18 | Roche Cobas Taqman | 170,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; HBeAg - ; HBcIgM - | 29-Mar-18 | $150.00 | Initial Date of Diagnosis | 10-Mar-18 | Additional Testing | ALT: 877 U/L | AST: 1094 U/L | Bilirubin: 135 umol/L | Creatinine: 69 umol/L | Chronic Hepatitis B | 13-Apr-18 | Current Signs and Symptoms | Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050157-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 8.00 | $150.00 | 50 Y | M | Asian | <-70C | 24-Apr-18 | Roche Cobas Taqman | 1,020 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 16-Apr-18 | $150.00 | Initial Date of Diagnosis | 2000 | Additional Testing | ALT: 142 U/L | AST: 281 U/L | Bilirubin: 388 umol/L | Creatinine: 57 umol/L | Chronic Hepatitis B | 2-Apr-18 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050157-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 10.00 | $150.00 | 50 Y | M | Asian | <-70C | 24-Apr-18 | Roche Cobas Taqman | 1,020 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + | 16-Apr-18 | $150.00 | Initial Date of Diagnosis | 2000 | Additional Testing | ALT: 142 U/L | AST: 281 U/L | Bilirubin: 388 umol/L | Creatinine: 57 umol/L | Chronic Hepatitis B | 2-Apr-18 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050164-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 9.00 | $150.00 | 43 Y | M | Asian | <-70C | 24-Apr-18 | Roche Cobas Taqman | 3,020,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBeAb + ; HBeAg + HBc Total + ; HBcIgM - ; | 20-Apr-18 | $150.00 | Initial Date of Diagnosis | 2011 | Additional Testing | ALT: 1167 U/L | AST: 334 U/L | Bilirubin: 382 umol/L | Creatinine: 74 umol/L | Chronic Hepatitis B | 1-Apr-18 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050164-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 10.00 | $150.00 | 43 Y | M | Asian | <-70C | 24-Apr-18 | Roche Cobas Taqman | 3,020,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBeAb + ; HBeAg + HBc Total + ; HBcIgM - ; | 20-Apr-18 | $150.00 | Initial Date of Diagnosis | 2011 | Additional Testing | ALT: 1167 U/L | AST: 334 U/L | Bilirubin: 382 umol/L | Creatinine: 74 umol/L | Chronic Hepatitis B | 1-Apr-18 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050170-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 7.00 | $150.00 | 35 Y | M | Asian | <-70C | 14-Mar-18 | Roche Cobas Taqman | 363,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; | 9-Mar-18 | $150.00 | Initial Date of Diagnosis | 2001 | Additional Testing | ALT: 676 U/L | AST: 1184 U/L | Bilirubin: 274 umol/L | Creatinine: 81 umol/L | Chronic Hepatitis B | 8-Mar-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050174-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 3.00 | $150.00 | 68 Y | M | Asian | <-70C | 17-Apr-18 | Roche Cobas Taqman | 168,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAb + ; 3-Apr-2018 ; Anti HBe + ; | 3-Apr-2018 | 9-Apr-2018 | $150.00 | Initial Date of Diagnosis | 3-Apr-18 | Additional Testing | ALT: 70 U/L | AST: 109 U/L | Bilirubin: 39.6 umol/L | Creatinine: 96 umol/L | Chronic Hepatitis B | 3-Apr-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050174-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 7.00 | $150.00 | 68 Y | M | Asian | <-70C | 17-Apr-18 | Roche Cobas Taqman | 168,000,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAb + ; 3-Apr-2018 ; Anti HBe + ; | 3-Apr-2018 | 9-Apr-2018 | $150.00 | Initial Date of Diagnosis | 3-Apr-18 | Additional Testing | ALT: 70 U/L | AST: 109 U/L | Bilirubin: 39.6 umol/L | Creatinine: 96 umol/L | Chronic Hepatitis B | 3-Apr-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | |||||||||||||||||
| DLS17-050178-K2 | Hepatitis B (HBV) | Vietnam | K2 EDTA Plasma | 1.00 | 6.00 | $150.00 | 31 Y | M | Asian | <-70C | 14-Mar-18 | Roche Cobas Taqman | 1,580,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; | 8-Mar-18 | $150.00 | Initial Date of Diagnosis | 8-Mar-18 | Additional Testing | ALT: 802 U/L | AST: 1041 U/L | Bilirubin: 49 umol/L | Creatinine: 45 umol/L | Acute Hepatitis B | 8-Mar-18 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| DLS17-050178-S | Hepatitis B (HBV) | Vietnam | Serum | 1.00 | 5.00 | $150.00 | 31 Y | M | Asian | <-70C | 14-Mar-18 | Roche Cobas Taqman | 1,580,000 IU/mL | HBV DNA | Hepatitis Serology Result | HBsAg + ; | 8-Mar-18 | $150.00 | Initial Date of Diagnosis | 8-Mar-18 | Additional Testing | ALT: 802 U/L | AST: 1041 U/L | Bilirubin: 49 umol/L | Creatinine: 45 umol/L | Acute Hepatitis B | 8-Mar-18 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | |||||||||||||||||
| KHBR-0054 | Hepatitis B (HBV) | USA | K2 EDTA Plasma | 1.00 | 1.00 | $40.00 | 58 Y | M | U/A | <-70C | 07-Mar-17 | Abbott Architect | Positive | HBV | $40.00 | GERD | Date of freeze | 03.16.17 | ||||||||||||||||||||||||||
| DLS0077175 | Hepatitis B (HBV) | USA | Serum | 1.00 | 1.00 | $55.00 | 34 Y | F | White | <-70C | 05-Feb-19 | PCR | Bioplex | 3,745 IU/mL | HBV | $55.00 | D25.1, Z01.411, O98.419, O34.29, O82, R10.9, Z86.32, K80.20, K82.8, B18.1, N73.9 | ||||||||||||||||||||||||||||
| DLS0101247 | Hepatitis B (HBV) | France | Citrated Plasma | 1.00 | 9.00 | $95.00 | 39 Y | M | U/A | <-70C | 18-Jun-12 | Elisa | 0.053 | Genotype | D | $95.00 | Mutation | Serotype | T118R Q129P | Not Tested | Procleix Ultrio Assay Novartis | Positive | Cobas Taqman HBV test | <6 UI/mL | Viral Load | Titer Ag HBs | Negative | HBc Result | Positive | Comments | U/A | |||||||||||||||
| KHBR19-00070 | Hepatitis B (HBV) | USA | Serum | 2.00 | 1.00 | $55.00 | 60 Y | M | Asian | <-70C | 30-Jan-19 | Abbott Architect | 7,504 | HBV | $55.00 | Freeze Date | 05.21.19 | |||||||||||||||||||||||||||
| DLS0089747 | Hepatitis B (HBV) | USA | Serum | 1.50 | 1.00 | $55.00 | 44 Y | M | White | <-70C | 01-Apr-19 | Bioplex PCR | 87 IU/mL | HBV DNA | $55.00 | B19.20, B19.10, K72.90, F19.10 | ||||||||||||||||||||||||||||
| DLS0091322 | Hepatitis B (HBV) | USA | Serum | 1.00 | 1.00 | $55.00 | 55 Y | M | Black | <-70C | 26-Apr-19 | Bioplex PCR | 182 IU/mL | HBV DNA | $55.00 | K21.9, Z79.01, Z95.2, Z98.890, R91.8, E78.00, N18.9, R80.9, I50.9, M10.9, M32.14, N18.3, E21.1, I15.1, Z79.899, M25.551 | ||||||||||||||||||||||||||||
| DLS0091590 | Hepatitis B (HBV) | USA | Serum | 1.50 | 1.00 | $55.00 | 35 Y | F | Asian | <-70C | 07-May-19 | PCR | 525 IU/mL | HBV | $55.00 | Z34.03, O09.893, O98.419, O42.90, O70.1, O80 | ||||||||||||||||||||||||||||
| KH19-090887 | Hepatitis B (HBV) | USA | L. Heparin Plasma | 1.50 | 1.00 | $55.00 | 68 Y | M | White | <-70C | 25-Jun-19 | COBAS(R) AmpliPrep | TaqMan(R) HBV Test v2.0 | 2,530,994 IU/mL | HBV | $55.00 | |||||||||||||||||||||||||||||
| KH19-093020 | Hepatitis B (HBV) | USA | Serum | 1.25 | 1.00 | $95.00 | 67 Y | M | White | <-70C | 07-May-19 | COBAS(R) AmpliPrep | COBAS(R) TaqMan(R) | HBV TEST, v2.0 | 58067552 IU/mL | HBV | $95.00 |
Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.
Please read carefully before purchasing:
Clinical specimens for research use only.
Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.
If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341
These products are supplied without warranty for suitability for specific applications or analytical determinations.
Specimens and data will be may be used for general biomarker research, assay and instrument validation purposes only. All Research products identified as “Diagnostic Remnant Samples” are human biological materials leftover from routine laboratory analysis and are de-identified (coded) to protect subject confidentiality. Under OHRP definition 45 CFR 46.102(f) these coded specimens are not considered subjects for Human research requiring informed consent. Specimens cannot be used for whole genomic sequencing of genetic material. Research products designated as “Clinical Research Samples” by “type” are obtained from IRB approved research study protocols with informed consent obtained from each subject enrolled. Specimens cannot be used for whole genomic sequencing of genetic material.